14% Growth, but PAT Leans on ₹30 Cr Insurance Gain—Normalized Earnings Only ₹15.4 Cr

The headline profit popped 78% year-on-year, but the call and the financials reveal the story: ₹30 crore of the ₹45.4 crore PAT is an insurance settlement, not operating earnings. Strip that out, and normalized profit is ₹15.4 crore, or 2.3% of revenue. That's a healthy quarter by absolute terms, but far from the 6.8% margin the headline implies.

The ₹662.4 crore revenue (+14.1% YoY) is real and on track for management's full-year double-digit guidance. EBITDA expanded 80 basis points to 13.4% (from 12.6% prior year), supporting the ₹300+ crore EBITDA target for the year. But the path to that profit is uneven. Flavour, the largest segment, delivered ₹112 crore, but management disclosed ~₹15 crore of that is inventory buildup driven by customer prepone orders during supply disruptions. Normalized Flavour run-rate is ₹95–96 crore per quarter. That means Q1 is not repeatable at headline rates. Global Ingredients was "softer than expected," and India Fragrance flat YoY despite the group's 14% growth—a sign that domestic demand is tougher than prior calls suggested.

Three material changes from prior calls: Net debt rose to ₹852 crore (vs. ₹800 crore prior guidance) due to ₹65 crore strategic inventory buildup and capex acceleration. Management reaffirmed deleveraging from Q3 onwards (₹25 crore per quarter), but the higher starting point signals a more expensive path back. India Fragrance is flat YoY, not growing with the group; management cites a "conscious exit from low-margin business," but the softness also hints at domestic market headwinds. Global Ingredients recovery was pushed to H2 from prior calls' implied gradual ramp; supply chain disruptions have extended the timeline. None of these is a cut to full-year guidance, but they are downgrades to the underlying momentum narrative.

The stock rallied +13.5% on day 1 post-result and held +14.3% by day 3, suggesting the market believed the 14% revenue growth and 80 bp margin gain. However, the price is now overbought on technicals (RSI 77.2) and sits 28% below its all-time high of ₹231.28, trading at ₹166.54. FII ownership edged up 63 bp to 7.42% (modest add), while DII trimmed 84 bp to 5.18%—a slight loss of domestic confidence. A small bulk trade on Jul 29 by Elixir Wealth (buy/sell at ₹166.61/₹166.30) shows no insider/promoter-linked activity. The fundamental read (solid revenue growth, lumpy earnings, elevated debt) does not yet justify an overbought technical setup.

S H Kelkar is executing on a legitimate multi-year strategy: double-digit revenue growth, EBITDA margin expansion, and long-cycle international ventures (Europe, USA, UK) aimed at 17–18% target ROCE. The Q1 result supports the revenue narrative and validates the margin path. But the quarter also reveals the complexity: reported PAT is inflated 66% by a one-time insurance gain, Flavour is lumpy with ₹15 crore of inventory pull-forward, and domestic fragrance demand is soft despite pricing discipline. Normalized earnings are half the headline, and the path to the ₹300+ crore EBITDA target depends on Flavour normalization, Global Ingredients recovery, and macro stability. Europe ventures remain 3–4 years from breakeven and are a long-term option, not a near-term driver.

The stock popped +13.5% on the result and is overbought on technicals (RSI 77.2). FII added modestly, DII trimmed—a sign that institutional confidence is cautious. At ₹166.54, down 28% from its all-time high but still extended after the rally, the stock prices in the revenue momentum but does not yet discount the earnings lumpiness and execution risks on debt and ventures. The number to track from here is normalized PAT (ex-insurance, ex-Flavour buildup). If Q2 confirms ₹15–17 Cr run-rate, the growth story is real but slower than the headline suggests. If it misses, the domestic headwind and inventory cycle are deeper than expected.